Today, a host of life sciences companies are utilizing gene therapy as a tool to find a cure for HIV. When discussing an HIV cure, there are two different possible targets: a “functional cure” where HIV is not eradicated but rather totally controlled without further ART treatment and a “sterilizing cure” that eliminates HIV completely from the body.
More than 40 cell and gene therapy companies call Philadelphia home. Their work is facilitated by academic/industrial partnerships with world-class scientists at Children’s Hospital of Philadelphia (CHOP), Temple University, Drexel University, and University of Pennsylvania. Led by Wilson, UPenn’s Gene Therapy Program has been a particularly strong catalyst of the growth that led to $3 billion in investment in cell and gene therapies (CGT) in 2021.
Robust Investment in Greater Philadelphia Region’s Cell and Gene Therapy Sector Continued in the First Quarter of 2021
Robust Investment in Greater Philadelphia Region’s Cell and Gene Therapy Sector Continued in the First Quarter of 2021 PHILADELPHIA (April 8, 2021) – The robust venture capital funding the Greater [….]